Exosome Diagnostics and Therapeutics Market - Global Forecast to 2032
| 出版年月 | 2024年6月 |
| ページ数 | 251 |
| 図表数 | 380 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The exosome diagnostics market is projected to grow from USD 59 million in 2024 to USD 2,347 million by 2029 at a CAGR of 108.9%.
エクソソーム診断市場は、2024 年の 5,900 万米ドルから 2029 年までに 23 億 4,700 万米ドルまで 108.9% の CAGR で成長すると予測されています。
However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, collectively exosome diagnostics and therapeutics market is expected to generate USD 59 million by 2024 and projected to reach USD 6,848 million in 2032 at a CAGR of 81.2%. Increasing number of clinical trials is expected to support the segment growth. Exosome-based therapies utilize vesicles released by cells to deliver therapeutic payloads. These vesicles offer advantages such as enhanced cargo bioavailability and the ability to cross biological barriers such as the blood-brain barrier. Despite these benefits, exosome therapies have not yet received regulatory approval. This is attributed to the challenges of standardizing exosome isolation and purification methods, scaling production, safety assurance, and regulatory processes. Companies such as Regeneus Ltd (Australia), CUREXSYS (Germany), and Direct Biologics LLC (US) are the key players in this segment that are focused on developing exosome-based therapeutics for clinical indications.
“Instruments & services segment is expected to grow at the fastest pace during the forecast period.”
Exosome characterization is done precisely through flow cytometry, nanoparticle tracking analysis, and ultracentrifugation in exosome diagnoses and treatments. The rising demand for exosome characterization & enrichment services is expected to support market growth. Some market players operating in the exosome diagnostics and therapeutics market also use their patented/proprietary technologies to offer end-to-end exosome services, including engineering, characterization, and purification. These players provide support services from a commercial viewpoint, targeted toward scalable exosome manufacturing and analysis from potential diagnostic samples such as blood, urine, and saliva.
“The urine source segment accounted for the largest share in the exosome diagnostics and therapeutics market in 2023.”
Rapid commercialization of urine sample-based diagnostic tests is set to drive market. Urinary exosomes, released by cells in the urine system, represent an emerging route for diagnosing and monitoring renal disorders. Their distinct characteristics, such as the capacity to shield their molecular cargo from degradation and contamination, make them primary candidates for renal dysfunction and structural injury biomarkers. The non-invasive method of urine collection and the stability and sufficiency of urinary exosomes highlight its potential for early disease detection and diagnosis.
“Cancer is expected to emerge as the dominant application segment in the exosome therapeutics market.”
Growing focus on oncology therapeutics is expected to propel the market growth. Exosomes also play a critical role in cancer therapy as carriers of therapeutic cargo, delivering drugs, RNA interference molecules, or immunomodulatory agents to target cancer cells. The University of Texas MD Anderson Cancer Center in Texas (US) is conducting clinical trials (NCT03608631) to study the optimal dosage effects and effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation. Despite these developments, challenges such as optimizing the exosome isolation technology and ensuring efficient delivery of therapeutic cargo to tumors are expected to hinder market growth during the forecast period.
North America dominates the global exosome diagnostics and therapeutics market throughout the forecast period.
The exosome diagnostics and therapeutics market is segmented into four regions: North America, Europe, the Asia Pacific (APAC), and the Rest of the World. As of April 2024, only one exosome-based diagnostic product has been approved and is available in the US. The US has thus emerged as a key revenue source for the global exosome diagnostics and therapeutics market, in turn making North America the dominant region in the market.
Breakdown of supply-side primary interviews by company type, designation, and region:
• By Respondent: Supply Side (70%), Demand side (30%)
• By Designation: C-level (55%), Director-level (20%), and Others (25%)
• By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)
List of Companies Profiled in the Report
• Bio-Techne (US)
• NanoFCM Inc. (UK)
• System Biosciences, LLC. (US)
• Capital Biosciences, Inc. (US)
• AMSBIO (UK)
• INOVIQ (Australia)
• Direct Biologics LLC (US)
• Regeneus Ltd (Australia)
• CUREXSYS (Germany)
• Aegle Therapeutics (US)
• Mercy Bioanalytics (US)
• multimmune GmbH (Germany)
• RION (US)
• Exogenus Therapeutics (Portugal)
• Everzom (France)
• Kimera Labs (US)
• NanoSomiX, Inc. (US)
• Exonox Biosciences, Inc. (Taiwan)
• Capricor Therapeutics, Inc. (US)
• Evox Therapeutics (US)
• ILIAS Biologics Inc. (Korea)
Research Coverage
This report studies the exosome diagnostics and therapeutics market based on type, product & service, source, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total exosome diagnostics and therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Drivers: The key factors driving the overall market growth emerging potential of exosome-based liquid biopsy, increasing collaborations & commercialization initiatives, and growing outsourcing of exosome manufacturing activities.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the exosome diagnostics and therapeutics market.
• Market Penetration: Comprehensive information on exosome diagnostics and therapeutics offered by the top 21 players in the market. The report analyzes the exosome diagnostics and therapeutics market by type, product & service, application, source, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of exosome diagnostics and therapeutics across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the exosome diagnostics and therapeutics market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the exosome diagnostics and therapeutics market
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 28
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
FIGURE 1 MARKET SEGMENTATION 28
1.3.2 REGIONS COVERED 29
FIGURE 2 REGIONAL SEGMENTATION 29
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 3 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 32
FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 33
2.2 MARKET ESTIMATION METHODOLOGY 33
FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 33
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 34
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 35
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 35
2.3 MARKET GROWTH RATE PROJECTIONS 37
FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 37
FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 RESEARCH ASSUMPTIONS 40
2.6 RISK ASSESSMENT ANALYSIS 40
TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS 40
2.7 RECESSION IMPACT ANALYSIS 40
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 40
TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 41
TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 41
3 EXECUTIVE SUMMARY 42
FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION) 42
FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION) 43
FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION) 43
FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION) 44
FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION) 45
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET 46
4 PREMIUM INSIGHTS 47
4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW 47
FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET 47
4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029) 48
FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029 48
4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION) 48
FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS 50
5.2.1 DRIVERS 50
5.2.1.1 Emerging potential of exosome-based liquid biopsy 50
5.2.1.2 Increasing initiatives for product commercialization 51
5.2.1.3 Growing outsourcing of exosome-based manufacturing activities 52
5.2.2 RESTRAINTS 52
5.2.2.1 Technical complexities associated with exosome isolation 52
5.2.2.2 Stringent regulatory requirements 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growing adoption of exosome biomarkers for personalized medicine 53
5.2.4 CHALLENGES 54
5.2.4.1 Inadequate protocols for exosome development & production 54
5.3 SUPPLY CHAIN ANALYSIS 54
FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 55
5.4 VALUE CHAIN ANALYSIS 56
FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE 56
5.5 PATENT ANALYSIS 57
5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS 57
FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013–OCTOBER 2023 58
FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION 58
5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS 59
FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013–OCTOBER 2023 59
FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION 60
5.6 REGULATORY LANDSCAPE 60
5.6.1 REGULATORY SCENARIO 60
5.6.1.1 North America 61
5.6.1.1.1 US 61
5.6.1.1.2 Canada 61
5.6.1.2 Europe 62
5.6.1.2.1 Germany 62
5.6.1.2.2 Spain 62
5.6.1.3 Asia Pacific 63
5.6.1.3.1 China 63
5.6.1.3.2 Japan 63
5.6.1.3.3 South Korea 64
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.7 PORTER’S FIVE FORCES ANALYSIS 67
TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 67
5.7.1 THREAT OF NEW ENTRANTS 67
5.7.2 THREAT OF SUBSTITUTES 67
5.7.3 BARGAINING POWER OF SUPPLIERS 68
5.7.4 BARGAINING POWER OF BUYERS 68
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 68
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 68
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS 68
5.8.2 BUYING CRITERIA FOR END USERS 70
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 70
5.9 INVESTMENT AND FUNDING SCENARIO 71
TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO 71
5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS 74
5.10.1 EXOSOME ISOLATION 74
TABLE 9 EXOSOME ISOLATION TECHNIQUES 75
5.10.2 EXOSOME CHARACTERIZATION AND QC 76
5.10.3 EXOSOME PRODUCTION 76
5.11 PIPELINE ANALYSIS 76
FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE 77
FIGURE 30 EXOSOME PIPELINE, BY PHASE 77
5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS 77
FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE 78
FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION 78
5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS 78
FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION 79
FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY 79
TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS 80
TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS 81
5.12 PRICING ANALYSIS 83
5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 83
TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER 83
5.12.2 AVERAGE SELLING PRICE TREND, BY REGION 83
5.13 ECOSYSTEM ANALYSIS 84
FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP 84
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85
FIGURE 36 REVENUE SHIFT AND NEW POCKETS 85
5.15 KEY CONFERENCES & EVENTS 86
TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024–2025) 86
5.16 TECHNOLOGY ANALYSIS 87
5.16.1 KEY TECHNOLOGIES 87
TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES 87
5.16.2 COMPLIMENTARY TECHNOLOGIES 88
5.16.3 ADJACENT TECHNOLOGIES 89
6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE 90
6.1 INTRODUCTION 91
TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 91
TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 91
6.2 EXOSOME DIAGNOSTICS 91
6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET 91
TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 92
TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030–2032 (USD MILLION) 92
TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 93
TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 93
TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 94
6.3 EXOSOME THERAPEUTICS 94
6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH 94
TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 95
TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION) 95
TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 96
TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 96
TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 97
7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 98
7.1 INTRODUCTION 99
TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 99
TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030–2032 (USD MILLION) 99
7.2 KITS & REAGENTS 99
7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET 99
TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022–2029 (USD MILLION) 100
TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030–2032 (USD MILLION) 100
TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION) 101
TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION) 101
TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION) 102
7.3 INSTRUMENTS & SERVICES 103
7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH 103
TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030–2032 (USD MILLION) 103
8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE 104
8.1 INTRODUCTION 105
TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 105
TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 105
8.2 STEM CELLS 106
8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET 106
TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030–2032 (USD MILLION) 106
TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION) 107
TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION) 108
TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION) 108
8.3 BLOOD & BLOOD PLASMA 109
8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND 109
TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030–2032 (USD MILLION) 109
TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION) 110
TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION) 111
TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION) 111
8.4 URINE 112
8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET 112
TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030–2032 (USD MILLION) 112
TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION) 113
TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION) 114
TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION) 114
8.5 OTHER SAMPLES 115
TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION) 115
TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030–2032 (USD MILLION) 115
TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION) 116
TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION) 117
TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION) 117
9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION 118
9.1 INTRODUCTION 119
TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 119
TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 119
9.2 CANCER 120
9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET 120
TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030–2032 (USD MILLION) 121
TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION) 121
TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION) 122
TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION) 123
9.3 DERMATOLOGICAL DISEASES 124
9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET 124
TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030–2032 (USD MILLION) 125
TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 125
TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 126
TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 127
9.4 MUSCULOSKELETAL DISORDERS 127
9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH 127
TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 128
TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030–2032 (USD MILLION) 129
TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION) 129
TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION) 130
TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION) 131
9.5 CARDIOVASCULAR DISEASES 132
9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH 132
TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030–2032 (USD MILLION) 132
TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 133
TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 134
TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 134
9.6 OTHER APPLICATIONS 135
TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030–2032 (USD MILLION) 135
TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION) 136
TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION) 137
TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION) 137
10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER 138
10.1 INTRODUCTION 139
TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 139
TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 139
10.2 HOSPITALS 139
10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET 139
TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030–2032 (USD MILLION) 140
TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION) 141
TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION) 142
TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION) 142
10.3 CLINICS AND PHYSICIAN SETTINGS 143
10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH 143
TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030–2032 (USD MILLION) 143
TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION) 144
TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION) 145
TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION) 145
11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION 146
11.1 INTRODUCTION 147
TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 147
TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION) 147
11.2 NORTH AMERICA 147
11.2.1 NORTH AMERICA: RECESSION IMPACT 148
FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT 148
TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 149
TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 150
TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 150
TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 150
TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 151
TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 151
TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 151
TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 152
11.2.2 US 152
11.2.2.1 Rising R&D initiatives for development of exosomes to drive market 152
TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 153
TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 153
TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 154
TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 154
TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 154
TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 155
TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 155
11.2.3 CANADA 155
11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth 155
TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 156
TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 156
TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 157
TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 157
TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 157
TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 158
TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 158
11.3 EUROPE 158
11.3.1 EUROPE: RECESSION IMPACT 158
FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT 159
TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 160
TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 161
TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 161
TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 161
TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 162
TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 162
TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 162
TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 163
11.3.2 GERMANY 163
11.3.2.1 Commercialization of pipeline candidates to propel market 163
TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 163
TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 164
TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 164
TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 164
TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 165
TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 165
TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 165
11.3.3 UK 166
11.3.3.1 Rising growth in life sciences research to drive market 166
TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 166
TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 167
TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 167
TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 167
TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 168
TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 168
TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 168
11.3.4 FRANCE 169
11.3.4.1 Presence of emerging players for exosome preparation to fuel market 169
TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 169
TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 169
TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 170
TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 170
TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 170
TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 171
TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 171
11.3.5 ITALY 171
11.3.5.1 Rising growth in biotech sector to boost demand 171
TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 172
TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 172
TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 173
TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 173
TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 173
TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 174
TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 174
11.3.6 SPAIN 174
11.3.6.1 Increasing initiatives for exosome research to support market growth 174
TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 175
TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 175
TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 175
TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 176
TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 176
TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 176
TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 177
11.3.7 REST OF EUROPE 177
TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 177
TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 178
TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 178
TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 178
TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 179
TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 179
TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 179
11.4 ASIA PACIFIC 180
11.4.1 ASIA PACIFIC: RECESSION IMPACT 180
TABLE 225 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 226 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 181
TABLE 227 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 228 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 181
TABLE 229 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 182
TABLE 230 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 182
TABLE 231 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 182
TABLE 232 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 183
TABLE 233 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 183
TABLE 234 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 183
11.4.2 JAPAN 184
11.4.2.1 Increasing healthcare expenditure to propel market 184
TABLE 235 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 236 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 184
TABLE 237 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 185
TABLE 238 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 185
TABLE 239 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 185
TABLE 240 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 186
TABLE 241 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 186
TABLE 242 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 186
11.4.3 CHINA 187
11.4.3.1 Rising incidence of chronic diseases to drive market 187
TABLE 243 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 244 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 187
TABLE 245 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 188
TABLE 246 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 188
TABLE 247 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 188
TABLE 248 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 189
TABLE 249 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 189
TABLE 250 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 189
11.4.4 INDIA 190
11.4.4.1 Increasing pool of start-ups and rising funding investments to fuel market 190
TABLE 251 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 252 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 190
TABLE 253 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 191
TABLE 254 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 191
TABLE 255 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 191
TABLE 256 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 192
TABLE 257 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 192
TABLE 258 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 192
11.4.5 SOUTH KOREA 193
11.4.5.1 Rising developments by leading market players to boost demand 193
TABLE 259 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 260 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 193
TABLE 261 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 194
TABLE 262 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 194
TABLE 263 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 194
TABLE 264 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 195
TABLE 265 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 195
TABLE 266 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 195
11.4.6 AUSTRALIA 196
11.4.6.1 Increasing adoption of novel therapeutics to support market growth 196
TABLE 267 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 268 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 196
TABLE 269 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 196
TABLE 270 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 197
TABLE 271 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 197
TABLE 272 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 197
TABLE 273 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 198
TABLE 274 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 198
11.4.7 REST OF ASIA PACIFIC 198
TABLE 275 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 276 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 199
TABLE 277 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 199
TABLE 278 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 199
TABLE 279 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 200
TABLE 280 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 200
TABLE 281 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 200
TABLE 282 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 201
11.5 REST OF THE WORLD 201
11.5.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET 201
TABLE 283 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 284 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 202
TABLE 285 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 202
TABLE 286 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 202
TABLE 287 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 203
TABLE 288 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 203
TABLE 289 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 203
TABLE 290 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 204
11.5.2 REST OF THE WORLD: RECESSION IMPACT 204
12 COMPETITIVE LANDSCAPE 205
12.1 OVERVIEW 205
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 205
FIGURE 39 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS (2021−2024) 205
12.3 REVENUE ANALYSIS 206
FIGURE 40 REVENUE ANALYSIS OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, 2022−2032 206
12.4 MARKET SHARE ANALYSIS 206
FIGURE 41 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SHARE ANALYSIS (2023) 207
TABLE 291 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEGREE OF COMPETITION 207
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 208
12.5.1 STARS 208
12.5.2 EMERGING LEADERS 208
12.5.3 PERVASIVE PLAYERS 208
12.5.4 PARTICIPANTS 208
FIGURE 42 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 209
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 210
12.5.5.1 Overall company footprint 210
TABLE 292 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OVERALL COMPANY FOOTPRINT 210
12.5.5.2 Regional footprint 210
TABLE 293 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: REGIONAL FOOTPRINT 210
12.5.5.3 Product & service footprint 211
TABLE 294 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PRODUCT & SERVICE FOOTPRINT 211
12.5.5.4 Type footprint 211
TABLE 295 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: TYPE FOOTPRINT 211
12.5.5.5 Application footprint 212
TABLE 296 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: APPLICATION FOOTPRINT 212
12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES, 2023 212
12.6.1 PROGRESSIVE COMPANIES 212
12.6.2 STARTING BLOCKS 212
12.6.3 DYNAMIC COMPANIES 213
12.6.4 RESPONSIVE COMPANIES 213
FIGURE 43 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 213
12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023 214
TABLE 297 EXOSOME THERAPEUTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 214
12.7 COMPETITIVE SCENARIO 215
12.7.1 DEALS 215
TABLE 298 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEALS, JANUARY 2021−APRIL 2024 215
12.7.2 OTHER DEVELOPMENTS 215
TABLE 299 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021−APRIL 2024 215
13 COMPANY PROFILES 216
(Business overview, Products/Solutions/Services offered, Recent developments & MnM View)*
13.1 KEY PLAYERS 216
13.1.1 BIO-TECHNE 216
TABLE 300 BIO-TECHNE: COMPANY OVERVIEW 216
FIGURE 44 BIO-TECHNE: COMPANY SNAPSHOT (2023) 217
TABLE 301 BIO-TECHNE: PRODUCTS/SERVICES OFFERED 218
TABLE 302 BIO-TECHNE: DEALS 218
TABLE 303 BIO-TECHNE: OTHER DEVELOPMENTS 219
13.1.2 NANOFCM INC. 221
TABLE 304 NANOFCM INC.: COMPANY OVERVIEW 221
TABLE 305 NANOFCM INC.: PRODUCTS/SERVICES OFFERED 221
13.1.3 SYSTEM BIOSCIENCES, LLC. 222
TABLE 306 SYSTEM BIOSCIENCES, LLC.: COMPANY OVERVIEW 222
TABLE 307 SYSTEM BIOSCIENCES, LLC.: PRODUCTS/SERVICES OFFERED 223
13.1.4 CAPITAL BIOSCIENCES, INC. 224
TABLE 308 CAPITAL BIOSCIENCES, INC.: COMPANY OVERVIEW 224
TABLE 309 CAPITAL BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 224
13.1.5 AMSBIO 225
TABLE 310 AMSBIO: COMPANY OVERVIEW 225
TABLE 311 AMSBIO: PRODUCTS/SERVICES OFFERED 225
13.1.6 INOVIQ 226
TABLE 312 INOVIQ: COMPANY OVERVIEW 226
FIGURE 45 INOVIQ: COMPANY SNAPSHOT (2023) 227
TABLE 313 INOVIQ: PRODUCTS/SERVICES OFFERED 227
TABLE 314 INOVIQ: DEALS 228
13.1.7 DIRECT BIOLOGICS LLC 229
TABLE 315 DIRECT BIOLOGICS: COMPANY OVERVIEW 229
TABLE 316 DIRECT BIOLOGICS: PRODUCTS/SERVICES OFFERED 229
TABLE 317 DIRECT BIOLOGICS: REGULATORY APPROVALS 230
TABLE 318 DIRECT BIOLOGICS: OTHER DEVELOPMENTS 230
13.1.8 REGENEUS LTD 231
TABLE 319 REGENEUS LTD: COMPANY OVERVIEW 231
TABLE 320 REGENEUS LTD: PRODUCTS/SERVICES OFFERED 231
13.1.9 CUREXSYS 232
TABLE 321 CUREXSYS: COMPANY OVERVIEW 232
TABLE 322 CUREXSYS: PRODUCTS/SERVICES OFFERED 232
13.1.10 AEGLE THERAPEUTICS 233
TABLE 323 AEGLE THERAPEUTICS: COMPANY OVERVIEW 233
TABLE 324 AEGLE THERAPEUTICS: PRODUCTS/SERVICES OFFERED 233
*Details on Business overview, Products/Solutions/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 234
13.2.1 MERCY BIOANALYTICS 234
TABLE 325 MERCY BIOANALYTICS: COMPANY OVERVIEW 234
13.2.2 NANOSOMIX, INC. 234
TABLE 326 NANOSOMIX, INC.: COMPANY OVERVIEW 234
13.2.3 EXONOX BIOSCIENCES, INC. 235
TABLE 327 EXONOX BIOSCIENCES, INC.: COMPANY OVERVIEW 235
13.2.4 MULTIMMUNE GMBH 236
TABLE 328 MULTIMMUNE GMBH: COMPANY OVERVIEW 236
13.2.5 CAPRICOR THERAPEUTICS, INC. 237
TABLE 329 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW 237
13.2.6 EVOX THERAPEUTICS 238
TABLE 330 EVOX THERAPEUTICS: COMPANY OVERVIEW 238
13.2.7 ILIAS BIOLOGICS INC. 239
TABLE 331 ILIAS BIOLOGICS, INC.: COMPANY OVERVIEW 239
13.2.8 RION 240
TABLE 332 RION: COMPANY OVERVIEW 240
13.2.9 EXOGENUS THERAPEUTICS 241
TABLE 333 EXOGENUS THERAPEUTICS: COMPANY OVERVIEW 241
13.2.10 EVERZOM 242
TABLE 334 EVERZOM: COMPANY OVERVIEW 242
13.2.11 KIMERA LABS 243
TABLE 335 KIMERA LABS: COMPANY OVERVIEW 243
14 APPENDIX 244
14.1 DISCUSSION GUIDE 244
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 247
14.3 CUSTOMIZATION OPTIONS 249
14.4 RELATED REPORTS 249
14.5 AUTHOR DETAILS 250
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11